Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2007
09/07/2007CA2643803A1 .beta. crystalline form of perindopril arginine salt, method for making same, and pharmaceutical compositions containing same
09/07/2007CA2643714A1 Aryl/alkyl vinyl sulfone hyaluronic acid derivatives
09/07/2007CA2643579A1 Benzochromenone derivatives useful as anti-angiogenesis and anti-cancer agents
09/07/2007CA2643559A1 Antiviral drugs for treatment of arenavirus infection
09/07/2007CA2643492A1 Nanoparticulate carvedilol formulations
09/07/2007CA2643360A1 A novel non-selective cation channel in neuronal cells and methods for treating brain swelling
09/07/2007CA2643320A1 Modulators of muscarinic receptors
09/07/2007CA2643282A1 Compositions and methods for effecting controlled posterior vitreous detachment
09/07/2007CA2643238A1 Improved antitumoral treatments
09/07/2007CA2643111A1 Targeted delivery of pharmaceutical compounds
09/07/2007CA2643100A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
09/07/2007CA2643044A1 Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
09/07/2007CA2643038A1 Hexose compounds to treat cancer
09/07/2007CA2643037A1 Compositions and methods for delivery of amino-functional drugs
09/07/2007CA2643030A1 Epinephrine dosing regimens
09/07/2007CA2643021A1 Imidazole-based compounds, compositions comprising them and methods of their use
09/07/2007CA2642973A1 Quinoline derivatives
09/07/2007CA2642969A1 Method for increasing lean musclse mass and decreasing adipose tissue
09/07/2007CA2642943A1 Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs
09/07/2007CA2642931A1 Cyclohexylamino, benzene, pyridine, and pyridazine derivatives
09/07/2007CA2642848A1 Methods and compositions to treat and detect misfolded-sod1 mediated diseases
09/07/2007CA2642813A1 Inhibitors of histone deacetylase
09/07/2007CA2642662A1 Compounds for the treatment of metabolic disorders
09/07/2007CA2642649A1 Modulators of muscarinic receptors
09/07/2007CA2642598A1 Selective androgen receptor modulators
09/07/2007CA2642424A1 Primary amines as renin inhibitors
09/07/2007CA2642368A1 Treatment of prevention of valvular heart disease with flibanserin
09/07/2007CA2642195A1 Fluvastatin sodium pharmaceutical compositions
09/07/2007CA2642189A1 Mannose derivatives for killing tumor cells
09/07/2007CA2642180A1 Fluvastatin sodium novel forms and preparation therof
09/07/2007CA2641781A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
09/07/2007CA2641624A1 Octahydro-pyrrolo[3,4-b] pyrrole derivatives and their use as histamine-3 receptor ligands
09/07/2007CA2641513A1 Methods of treating inflammatory and autoimmune diseases with natalizumab
09/07/2007CA2641160A1 Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
09/07/2007CA2641145A1 Sigma receptor compounds
09/07/2007CA2641144A1 Pyrazole derivatives as sigma receptor inhibitors
09/07/2007CA2640757A1 Imidazole compounds having pharmaceutical activity towards the sigma receptor
09/07/2007CA2640754A1 Pyrazole derivatives as sigma receptors antagonists
09/07/2007CA2640753A1 Sigma receptor inhibitors
09/07/2007CA2640738A1 Hydroxylamines and derivatives for the inhibition of complement activation
09/07/2007CA2640575A1 Compositions and methods for inducing bone growth and inhibiting bone loss
09/07/2007CA2638797A1 Galactose derivative, drug carrier and medicinal composition
09/07/2007CA2638768A1 Antimicrobial releasing polymers
09/07/2007CA2638734A1 Inhibitors of the unfolded protein response and methods for their use
09/07/2007CA2636431A1 Steroidal compounds as steroid sulphatase inhibitors
09/07/2007CA2635280A1 Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
09/07/2007CA2633803A1 Soft protease inhibitors and pro-soft forms thereof
09/07/2007CA2633464A1 Compositions and methods for dermal delivery of drugs
09/07/2007CA2633069A1 New 3'-, 7-substituted indirubins and their applications
09/07/2007CA2628964A1 Formulations of fispemifene
09/07/2007CA2614639A1 Pharmaceutical composition for treatment of blood clotting disorder
09/07/2007CA2611577A1 Antibiotic kit and composition and uses thereof
09/06/2007US20070209082 Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
09/06/2007US20070208347 Spine distraction implant and method
09/06/2007US20070208185 Intermediates for the hemisynthesis of taxanes and preparation processes therefor
09/06/2007US20070208179 Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
09/06/2007US20070208176 Biphenyl derivatives
09/06/2007US20070208167 Compounds and methods for modulating activation of NF-kappaB
09/06/2007US20070208166 Tao Kinase Modulators And Method Of Use
09/06/2007US20070208087 Compounds, compositions and methods for the treatment of inflammatory diseases
09/06/2007US20070208086 Ubiquinone analogs and methods of use
09/06/2007US20070208085 Potent cytotoxicity and inhibition of pan-cell cycle progression by an alkylating anthraquinone
09/06/2007US20070208084 Enantiomers of O-desmethyl venlafaxine
09/06/2007US20070208083 para-methyl-trans-N-(4-hydroxy-3-methoxy-benzyl)-cinnamic acid amide in the form of pure isomer; reacting para-tert.-butylbenzaldehyde in presence of piperidine base with malonic acid to form para-alkyl substituted cinnnamic acid, reacting intermeidate with 4-hydroxy-3-methoxybenzylamine; analgesic
09/06/2007US20070208082 Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
09/06/2007US20070208081 Oligomeric Compounds
09/06/2007US20070208080 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea
09/06/2007US20070208079 Inhibitors of nuclear factor kappa B (NF- kappa B) and inhibit the activity of the endothelin receptor; inhibit cell proliferation and for the induction of apoptosis
09/06/2007US20070208078 Novel phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient
09/06/2007US20070208077 Adiponectin Enhancer
09/06/2007US20070208076 Injectable chemotherapeutic solution of Erythrosin B, Phloxine B, Rose Bengal, 4,5,6,7-Tetrabromoerythrosin or their salts in a hydrophilic vehicle containing sodium, potassium, calcium or magnesium chloride, phosphate, or nitrate; low levels of pyrogens and particles
09/06/2007US20070208075 Pharmaceutical compositions
09/06/2007US20070208074 Methods and compositions for treating and preventing tumors
09/06/2007US20070208073 Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients
09/06/2007US20070208072 Maleate salt of tegaserod and crystalline forms thereof
09/06/2007US20070208071 Oxidative Degradation Products of Atorvastatin Calcium
09/06/2007US20070208070 2-thioxo-4-imidazolines; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders
09/06/2007US20070208069 Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
09/06/2007US20070208068 Aqueous Composition Comprising Thiazole Derivative
09/06/2007US20070208067 Tablet Formulations and Processes
09/06/2007US20070208066 ER-beta-selective ligands
09/06/2007US20070208065 Such as 5-[4-(1,1-dimethylethyl)phenyl]-N-hydroxy-4-phenyl-2-oxazolchexanamide which inhibits production of IL-6 and/or TNF alpha by inflammatory cytokines; inflammatory diseases, autoimmune diseases
09/06/2007US20070208064 Ion channel modulators
09/06/2007US20070208063 Imidazole-based compounds, compositions comprising them and methods of their use
09/06/2007US20070208062 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections
09/06/2007US20070208061 N-(1-(5-(2-(1H-indol-3-yl)ethyl)-4-(2,4-dimethoxybenzyl)-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethyl)-2-amino-2-methylpropanamide; useful for treating growth retardation, cachexia, obesity, food intake, energy balance, tumor cell proliferation, wound/burn healing, metabolic disorders and inflammation.
09/06/2007US20070208060 Compounds for treating inflammatory diseases
09/06/2007US20070208059 Therapeutic Agents
09/06/2007US20070208058 Stable Pharmaceutical Compositions and Methods of Making and Using Same
09/06/2007US20070208057 Methods And Compositions Using Thalidomide For The Treatment And Management Of Cancers And Other Diseases
09/06/2007US20070208056 Piperidinyl derivatives as modulators of chemokine receptor activity
09/06/2007US20070208055 Alternative synthesis of renin inhibitors and intermediates thereof
09/06/2007US20070208054 Macrocyclic factor viia inhibitors useful as anticoagulants
09/06/2007US20070208053 Fused heterobicyclic kinase inhibitors
09/06/2007US20070208052 Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
09/06/2007US20070208051 Novel N-(Alkoxyalkyl) Carbamoyl-Substituted 6-Phenyl-Benzonaphthyridine Derivatives and their Use as Pde 3/4 Inhibitors
09/06/2007US20070208050 Process for preparing irinotecan
09/06/2007US20070208049 e.g. 1-(2,6-Difluorobenzyl)-5-(3-Mehthoxyphenyl)-6-Methyl-3-[N-Methyl -N -(2-Pyridylethyl)Aminoethyl]Uracil; anticarcinoganic agent; prostate cancer, benign prostatic hypertrophy, breast cancer and endometriosis
09/06/2007US20070208048 New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators
09/06/2007US20070208047 administering Elvucitabine for treatment of hepatitis B and/or human immunodeficiency virus